BioPharma Resources

Drug Trial Radar · NCT07540897

A Study to Evaluate the Efficacy, Safety and Tolerability of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 - 304)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (Brilliance NT1 Study 304)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 13, 2026

Primary completion

Jun 2027

Study completion Jul 2027

Sponsor

Lead sponsor
Alkermes, Inc.Industry
Sponsor type
Industry
First posted
Apr 21, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.

Conditions

  • Narcolepsy Type 1

Interventions

  • ALKS 2680 Dose 1Drug

    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

  • ALKS 2680 Dose 2Drug

    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

  • PlaceboDrug

    Participants will receive placebo tablets, daily, orally for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose levelTime frame: Baseline to Week 12

Locations

53 sites in 13 countries. Site status is shown where the registry gives one.

  • Alkermes Investigational Site

    Scottsdale, Arizona · Recruiting

  • Alkermes Investigational Site

    Brandon, Florida · Recruiting

  • Alkermes Investigational Site

    Miami, Florida · Recruiting

  • Alkermes Investigational Site

    Winter Park, Florida · Recruiting

  • Alkermes Investigational Site

    Atlanta, Georgia · Recruiting

  • Alkermes Investigational Site

    Macon, Georgia · Recruiting

  • Alkermes Investigational Site

    Kansas City, Kansas · Recruiting

  • Alkermes Investigational Site

    Lansing, Michigan · Recruiting

  • Alkermes Investigational Site

    Novi, Michigan · Recruiting

  • Alkermes Investigational Site

    Rochester, Minnesota · Recruiting

  • Alkermes Investigational Site

    St Louis, Missouri · Recruiting

  • Alkermes Investigational Site

    Amherst, New York · Recruiting

  • Alkermes Investigational Site

    Charlotte, North Carolina · Recruiting

  • Alkermes Investigational Site

    Raleigh, North Carolina · Recruiting

  • Alkermes Investigational Site

    Cincinnati, Ohio · Recruiting

  • Alkermes Investigational Site

    Cleveland, Ohio · Recruiting

  • Alkermes Investigational Site

    Charleston, South Carolina · Recruiting

  • Alkermes Investigational Site

    Colombia, South Carolina · Recruiting

  • Alkermes Investigational Site

    Dallas, Texas · Recruiting

  • Alkermes Investigational Site

    El Paso, Texas · Recruiting

  • Alkermes Investigational Site

    Frisco, Texas · Recruiting

  • Alkermes Investigational Site

    McKinney, Texas · Recruiting

  • Alkermes Investigational Site

    San Antonio, Texas · Recruiting

  • Alkermes Investigational Site

    Sugar Land, Texas · Recruiting

  • Alkermes Investigational Site

    Norfolk, Virginia · Recruiting

  • Alkermes Investigational Site

    Spokane, Washington · Recruiting

  • Alkermes Investigational Site

    Macquarie Park, New South Wales, Australia · Recruiting

  • Alkermes Investigational Site

    Edegem, Belgium · Recruiting

  • Alkermes Investigational Site

    Ghent, Belgium · Recruiting

  • Alkermes Investigational Site

    Namur, Belgium · Recruiting

  • Alkermes Investigational Site

    Markham, Ontario, Canada · Recruiting

  • Alkermes Investigational Site

    Toronto, Ontario, Canada · Recruiting

  • Alkermes Investigational Site

    Sherbrooke, Quebec, Canada · Recruiting

  • Alkermes Investigational Site

    Helsinki, Finland · Recruiting

  • Alkermes Investigational Site

    Schwerin, Mecklenburg-Vorpommern, Germany · Recruiting

  • Alkermes Investigational Site

    Berlin, State of Berlin, Germany · Recruiting

  • Alkermes Investigational Site

    Berlin, State of Berlin, Germany · Recruiting

  • Alkermes Investigational Site

    Bologna, Italy · Recruiting

  • Alkermes Investigational Site

    Verona, Italy · Recruiting

  • Alkermes Investigational Site

    Kitakyushu, Fukuoka, Japan · Recruiting

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.